Inventor · disambiguated record
Matthew Volgraf
Also filed as: VOLGRAF MATTHEW
19 granted patents·8 pending applications·22 citations·filing 2006–2024
90Inventor score
Top patents by PatentIndex Score
27 records- 0187US10710994B2Oxadiazole transient receptor potential channel inhibitorsGENENTECH INC·Filed 2019·Granted Jul 14, 2020·3 cites·38 claims
- 0284US10179782B2Substituted sulfonamide compoundsGENENTECH INC·Filed 2016·Granted Jan 15, 2019·5 cites·10 claims
- 0382US9097707B2Photoreactive regulator of protein function and methods of use thereofUNIV CALIFORNIA·Filed 2012·Granted Aug 4, 2015·2 cites·10 claims
- 0482US8309350B2Photoreactive regulator of protein function and methods of use thereofISACOFF EHUD Y·Filed 2012·Granted Nov 13, 2012·4 cites·10 claims
- 0582US2025122184A1Oxadiazole transient receptor potential channel inhibitorsGENENTECH INC·Filed 2024·Application pending·0 cites
- 0681US8114843B2Photoreactive regulator of protein function and methods of use thereofISACOFF EHUD Y·Filed 2006·Granted Feb 14, 2012·4 cites·13 claims
- 0779US8178496B2Photoreactive regulator of glutamate receptor function and methods of use thereofTRAUNER DIRK·Filed 2008·Granted May 15, 2012·4 cites·7 claims
- 0877US12202824B2Oxadiazole transient receptor potential channel inhibitorsGENENTECH INC·Filed 2022·Granted Jan 21, 2025·0 cites·17 claims
- 0975US2025115618A1Sulfonimidamide compounds as inhibitors of interleukin-1 activityGENENTECH INC·Filed 2024·Application pending·0 cites
- 1068US11655245B2Oxadiazole transient receptor potential channel inhibitorsGENENTECH INC·Filed 2020·Granted May 23, 2023·0 cites·48 claims
- 1168US2024391930A1Spirocyclic bicyclic modulators of cholesterol biosynthesis and their use for promoting remyelinationGENENTECH INC·Filed 2024·Application pending·0 cites
- 1267US2024400579A1Spirocyclic modulators of cholesterol biosynthesis and their use for promoting remyelinationGENENTECH INC·Filed 2024·Application pending·0 cites
- 1367US2024398781A1Spirocyclic cyclic modulators of cholesterol biosynthesis and their use for promoting remyelinationGENENTECH INC·Filed 2024·Application pending·0 cites
- 1462US2024228463A1Sodium channel inhibitors and methods of designing sameGENENTECH INC·Filed 2024·Application pending·0 cites
- 1561US12234245B2Sulfonimidamide compounds as inhibitors of interleukin-1 activityGENENTECH INC·Filed 2021·Granted Feb 25, 2025·0 cites·19 claims
- 1659US9629911B2Photoreactive regulator of protein function and methods of use thereofUNIV CALIFORNIA·Filed 2015·Granted Apr 25, 2017·0 cites·7 claims
- 1756US10647731B2Thiazolopyrimidinones and methods of use thereofGENENTECH INC·Filed 2018·Granted May 12, 2020·0 cites·70 claims
- 1854US11560391B2Sulfonylurea compounds as inhibitors of interleukin-1 activityGENENTECH INC·Filed 2021·Granted Jan 24, 2023·0 cites·21 claims
- 1952US10913742B2Oxadiazolones as transient receptor potential channel inhibitorsGENENTECH INC·Filed 2019·Granted Feb 9, 2021·0 cites·13 claims
- 2051US10766878B2Sulfonylcycloalkyl carboxamide compoundsGENENTECH INC·Filed 2019·Granted Sep 8, 2020·0 cites·23 claims
- 2150US10695348B2Sulfonyl pyridyl TRP inhibitorsGENENTECH INC·Filed 2019·Granted Jun 30, 2020·0 cites·10 claims
- 2248US10711004B2Oxadiazole transient receptor potential channel inhibitorsGENENTECH INC·Filed 2019·Granted Jul 14, 2020·0 cites·23 claims
- 2347US10597383B2Bicyclic proline compoundsGENENTECH INC·Filed 2019·Granted Mar 24, 2020·0 cites·19 claims
- 2444US9988400B2Thiazolopyrimidinones and methods of use thereofGENENTECH INC·Filed 2016·Granted Jun 5, 2018·0 cites·70 claims
- 2543US10280165B2Pyridopyrimidinones and methods of use thereofGENENTECH INC·Filed 2017·Granted May 7, 2019·0 cites·28 claims
- 2639US2012065195A1Compounds for treating neurodegenerative diseasesCLARK CHRISTOPHER T·Filed 2011·Application pending·0 cites
- 2735US2012157448A1Compounds for treating neurodegenerative diseasesCOOK ADAM·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthew Volgraf files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →